Weitao Shen

No. 1838 Guangzhou Road
Guangzhou, 510515, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

The TFDP2-PDK3 axis drives glucose metabolic reprogramming to promote radioresistance in nasopharyngeal carcinoma.

The TFDP2-PDK3 axis drives glucose metabolic reprogramming to promote radioresistance in nasopharyngeal carcinoma.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: November 14, 2025

TGM2-TUFM promotes acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC through p62-mediated lipophagy.

TGM2-TUFM promotes acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC through p62-mediated lipophagy.

Journal: Respiratory research

Published: November 08, 2025

ALDH1L2 induces resistance to chemotherapy in small cell lung cancer by inhibiting ferroptosis.

ALDH1L2 induces resistance to chemotherapy in small cell lung cancer by inhibiting ferroptosis.

Journal: Redox biology

Published: August 26, 2025

Integrated insights into gut microbiota and metabolomic landscape in breast cancer patients undergoing adjuvant endocrine therapy.

Integrated insights into gut microbiota and metabolomic landscape in breast cancer patients undergoing adjuvant endocrine therapy.

Journal: mSystems

Published: August 15, 2025

PPP2R2C confers radioresistance in nasopharyngeal carcinoma by suppressing ferroptosis via RPS27L stabilization.

PPP2R2C confers radioresistance in nasopharyngeal carcinoma by suppressing ferroptosis via RPS27L stabilization.

Journal: Cell death & disease

Published: July 16, 2025

KDM4B/DHX9 promotes chemoresistance in small-cell lung cancer through the MYCN-driven signaling pathway.

KDM4B/DHX9 promotes chemoresistance in small-cell lung cancer through the MYCN-driven signaling pathway.

Journal: Oncogene

Published: May 29, 2025

VANGL2 downregulates HINT1 to inhibit the ATM-p53 pathway and promote cisplatin resistance in small cell lung cancer.

VANGL2 downregulates HINT1 to inhibit the ATM-p53 pathway and promote cisplatin resistance in small cell lung cancer.

Journal: Cell death discovery

Published: November 15, 2024

HMGB1 promotes chemoresistance in small cell lung cancer by inducing PARP1-related nucleophagy.

HMGB1 promotes chemoresistance in small cell lung cancer by inducing PARP1-related nucleophagy.

Journal: Journal of advanced research

Published: August 21, 2023

METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy.

METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy.

Journal: Journal of experimental & clinical cancer research : CR

Published: October 10, 2022

PARP1 controls the transcription of CD24 by ADP-ribosylating the RNA helicase DDX5 in pancreatic cancer.

PARP1 controls the transcription of CD24 by ADP-ribosylating the RNA helicase DDX5 in pancreatic cancer.

Journal: The international journal of biochemistry & cell biology

Published: September 15, 2022

THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients.

THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients.

Journal: Drug design, development and therapy

Published: February 26, 2022

NRBF2 regulates the chemoresistance of small cell lung cancer by interacting with the P62 protein in the autophagy process.

NRBF2 regulates the chemoresistance of small cell lung cancer by interacting with the P62 protein in the autophagy process.

Journal: iScience

Published: November 04, 2021

Showing 1-12 of 22

Last Updated: 09/26/2026